{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["69(3)"],"submitter":["Carrasco-Sanchez FJ"],"pubmed_abstract":["<h4>Background</h4>This consensus aims to clarify the role of Dipeptidyl Peptidase-4 inhibitors (iDPP-4) in managing patients with diabetes during the COVID-19 pandemic.<h4>Materials and methods</h4>A PubMed bibliographic search was carried out (December 2019-February 2021). Oxford methodology was used for the evaluation of evidence and possible recommendations were established by consensus.<h4>Results</h4>Diabetes appears to be an independent factor in COVID-19 disease (evidence 2b). No increased risk of contagion with iDPP-4 is demonstrated (evidence 2b), and its use has been shown to be safe (evidence 2b). The use of this drug may present a specific benefit in reducing mortality, particularly in in-hospital use (evidence 2a), reducing admission to intensive care units (evidence 2b) and "],"journal":["Endocrinologia, diabetes y nutricion"],"pagination":["209-218"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8570981"],"repository":["biostudies-literature"],"pubmed_title":["[Executive Summary from Expert consensus on effectiveness and safety of iDPP-4 in the treatment of patients with diabetes and COVID-19]."],"pmcid":["PMC8570981"],"pubmed_authors":["Carrasco-Sanchez FJ","Ruiz Quintero MA","Merino-Torres JF","Gargallo MA","Pines Corrales PJ","Gomez-Huelgas R","Orozco-Beltran D","Carretero-Anibarro E"],"additional_accession":[]},"is_claimable":false,"name":"[Executive Summary from Expert consensus on effectiveness and safety of iDPP-4 in the treatment of patients with diabetes and COVID-19].","description":"<h4>Background</h4>This consensus aims to clarify the role of Dipeptidyl Peptidase-4 inhibitors (iDPP-4) in managing patients with diabetes during the COVID-19 pandemic.<h4>Materials and methods</h4>A PubMed bibliographic search was carried out (December 2019-February 2021). Oxford methodology was used for the evaluation of evidence and possible recommendations were established by consensus.<h4>Results</h4>Diabetes appears to be an independent factor in COVID-19 disease (evidence 2b). No increased risk of contagion with iDPP-4 is demonstrated (evidence 2b), and its use has been shown to be safe (evidence 2b). The use of this drug may present a specific benefit in reducing mortality, particularly in in-hospital use (evidence 2a), reducing admission to intensive care units (evidence 2b) and ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-06-01T00:30:15.726Z","creation":"2025-06-01T00:30:15.726Z"},"accession":"S-EPMC8570981","cross_references":{"pubmed":["34778721"],"doi":["10.1016/j.endinu.2021.10.003"]}}